

THE AI STARTUP UNIVERSE: A COMPANY SNAPSHOT



SINCE 2011



LEADERSHIP

WIM VAN HECKE
CEO

JAN VERHEYDEN
COO

MICHIEL ROELS
CFO

ANNEMIE RIBBENS
VP Clinical Trials

DIRK SMEETS
VP Clinical Applications



CLIENTS

>120

clients worldwide



PARTNERSHIPS



BUSINESS MODEL

Annual subscription for entire portfolio based on institution size (volume) and needs (features).



INVESTMENTS ROUNDS

TOTAL FUNDING

\$20.2M



BRIEF HISTORY

2011 – Founded as a spin-off from UAntwerpen, KU Leuven, UZA and UZ Leuven.

2015 – CE marking for the first icobrain product for **brain MR**.


2016 – FDA-clearance for icobrain product for applications like **multiple sclerosis**. Launch US office.

2017 – FDA clearance for icobrain product for applications like **dementia** and **brain trauma**.

2018 – Launch of the first FDA-cleared deep learning based **image segmentation algorithm** for brain CT.



AREA OF EXPERTISE/ CURRENT SOLUTIONS:



- icobrain:** CE/FDA cleared automated extraction of clinically relevant measures from brain scans;
- icompanion:** digital patient-reported outcome platform for people with multiple sclerosis.



MODALITIES COVERED



MRI
CT



STEP OF THE RADIOLOGIST JOURNEY




IMAGE PROCESSING, DETECTION, LABELING AND REPORTING, PATIENT COMMUNICATION, PERFORMANCE MANAGEMENT



VISION FOR THE FUTURE

Product Development Roadmap:

Expansion of the icobrain portfolio in **2019** for applications like **epilepsy** and **stroke**.

Launch of the icompanion patient app for people with Multiple Sclerosis.



How do you see the future of the AI ecosystem?

Medical imaging AI is a fundamental tool for radiology in the transformation towards tomorrow's patient care. Data quality, workflow integration, and strategic partnerships are crucial in the realization of this goal.

What is your role in it?

icomatrix takes the capabilities of AI beyond radiology workflow optimization, all the way to the individual patient.